EP2149561A4 - Tetrahydroisoquinolin-1-one derivative or salt thereof - Google Patents

Tetrahydroisoquinolin-1-one derivative or salt thereof

Info

Publication number
EP2149561A4
EP2149561A4 EP08764654A EP08764654A EP2149561A4 EP 2149561 A4 EP2149561 A4 EP 2149561A4 EP 08764654 A EP08764654 A EP 08764654A EP 08764654 A EP08764654 A EP 08764654A EP 2149561 A4 EP2149561 A4 EP 2149561A4
Authority
EP
European Patent Office
Prior art keywords
tetrahydroisoquinolin
derivative
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP08764654A
Other languages
German (de)
French (fr)
Other versions
EP2149561A1 (en
EP2149561B1 (en
Inventor
Hiroyuki Hisamichi
Itsuro Shimada
Tsukasa Ishihara
Tomofumi Takuwa
Takafumi Shimizu
Noriko Ishikawa
Kyoichi Maeno
Norio Seki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Seldar Pharma Inc
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40075016&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP2149561(A4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Priority to PL08764654T priority Critical patent/PL2149561T3/en
Priority to SI200831545T priority patent/SI2149561T1/en
Publication of EP2149561A1 publication Critical patent/EP2149561A1/en
Publication of EP2149561A4 publication Critical patent/EP2149561A4/en
Application granted granted Critical
Publication of EP2149561B1 publication Critical patent/EP2149561B1/en
Priority to HRP20151336TT priority patent/HRP20151336T1/en
Priority to CY20151101112T priority patent/CY1117004T1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
EP08764654.3A 2007-05-28 2008-05-26 Tetrahydroisoquinolin-1-one derivative or salt thereof Active EP2149561B1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
PL08764654T PL2149561T3 (en) 2007-05-28 2008-05-26 Tetrahydroisoquinolin-1-one derivative or salt thereof
SI200831545T SI2149561T1 (en) 2007-05-28 2008-05-26 Tetrahydroisoquinolin-1-one derivative or salt thereof
HRP20151336TT HRP20151336T1 (en) 2007-05-28 2015-12-07 Tetrahydroisoquinolin-1-one derivative or salt thereof
CY20151101112T CY1117004T1 (en) 2007-05-28 2015-12-08 OUTPUT OF TETRAHYDROSOKINOLIN-1-ONE

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007140097 2007-05-28
PCT/JP2008/059621 WO2008146774A1 (en) 2007-05-28 2008-05-26 Tetrahydroisoquinolin-1-one derivative or salt thereof

Publications (3)

Publication Number Publication Date
EP2149561A1 EP2149561A1 (en) 2010-02-03
EP2149561A4 true EP2149561A4 (en) 2011-09-07
EP2149561B1 EP2149561B1 (en) 2015-09-09

Family

ID=40075016

Family Applications (1)

Application Number Title Priority Date Filing Date
EP08764654.3A Active EP2149561B1 (en) 2007-05-28 2008-05-26 Tetrahydroisoquinolin-1-one derivative or salt thereof

Country Status (23)

Country Link
US (5) US8486970B2 (en)
EP (1) EP2149561B1 (en)
JP (1) JP5336359B2 (en)
KR (3) KR101682638B1 (en)
CN (1) CN101668747B (en)
AU (1) AU2008255815B2 (en)
BR (1) BRPI0812359A2 (en)
CA (1) CA2688326C (en)
CY (1) CY1117004T1 (en)
DK (1) DK2149561T3 (en)
ES (1) ES2558677T3 (en)
HR (1) HRP20151336T1 (en)
HU (1) HUE026316T2 (en)
IL (1) IL202301A (en)
MX (1) MX2009012779A (en)
PL (1) PL2149561T3 (en)
PT (1) PT2149561E (en)
RS (1) RS54429B1 (en)
RU (1) RU2479578C2 (en)
SI (1) SI2149561T1 (en)
TW (1) TWI425945B (en)
WO (1) WO2008146774A1 (en)
ZA (1) ZA200908220B (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201111379A (en) 2009-09-09 2011-04-01 Vifor Int Ag Novel thiazole-and oxazole-hepcidine-antagonists
CN107109701B (en) * 2014-09-16 2020-10-09 斯坦福国际研究院 Discovery of affinity reagents and catalysts by fiber array scanning techniques
MX2018009870A (en) * 2016-02-15 2018-11-29 Cemm Forschungszentrum Fuer Molekulare Medizin Gmbh Taf1 inhibitors for the therapy of cancer.
US10875834B2 (en) 2016-07-22 2020-12-29 Virginia Commonwealth University Prodrug and protected forms of 5-hydroxymethylfurfuranal (5-HMF) and its derivatives
US11311528B2 (en) 2018-03-20 2022-04-26 Merck Sharp & Dohme Corp. Oxo-tetrahydro-isoquinoline carboxylic acids as STING inhibitors
CN110563687B (en) * 2019-07-23 2022-09-30 上海合全医药有限公司 Preparation method of 4- (aminomethyl) chroman-3-ol
EP4074314A1 (en) * 2021-04-15 2022-10-19 Valdospan GmbH Isoquinoline derivatives for use as antiviral and antitumour agents
CA3214899A1 (en) 2021-04-15 2022-10-20 Lutz Weber Isoquinoline derivatives for use as antiviral and antitumour agents
CN113603625B (en) * 2021-08-12 2023-03-10 南京卓康医药科技有限公司 Synthetic method of ketorolac intermediate
WO2024083802A1 (en) 2022-10-17 2024-04-25 Valdospan Gmbh Isoquinoline derivatives as protein degraders, e7 degraders, antivirals, tumor therapeutics and immune suppressives

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006115135A1 (en) * 2005-04-21 2006-11-02 Astellas Pharma Inc. Therapeutic agent for irritable bowel syndrome

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL110172A (en) * 1993-07-22 2001-10-31 Lilly Co Eli Bicyclic compounds and pharmaceutical compositions containing them
EP1155001A4 (en) * 1999-02-22 2003-05-28 Lion Bioscience Ag Isoquinoline derivatives and isoquinoline combinatorial libraries
NZ519380A (en) * 1999-12-28 2004-10-29 Eisai Co Ltd Heterocyclic compounds having sulfonamide groups
EP1944292B9 (en) * 2000-10-31 2016-07-06 Rensselaer Polytechnic Institute 8-substituted-2,6-methano-3-benzazocines and 3-substituted morphinanes as opioid receptor binding agents
AR035513A1 (en) * 2000-12-23 2004-06-02 Hoffmann La Roche DERIVATIVES OF TETRAHYDROPIRIDINE, PROCESS TO PREPARE THEM, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND USE OF SUCH COMPOUNDS IN THE PREPARATION OF MEDICINES
DE10146867A1 (en) 2001-09-24 2003-04-24 Bayer Ag tetrahydroisoquinolines
US20050124614A1 (en) * 2002-07-03 2005-06-09 Axys Pharmaceuticals, Inc. 3,4-Dihydroisoquinolin-1-one derivatives as inducers of apoptosis
MXPA05009508A (en) * 2003-03-07 2005-12-14 Lilly Co Eli 6-substituted nicotinamide derivatives as opioid receptor antagonists.
GB0305575D0 (en) 2003-03-11 2003-04-16 Glaxo Group Ltd Novel compounds
US7056930B2 (en) * 2003-04-14 2006-06-06 Pfizer Inc. 2-Azabicyclo[3.3.1]nonane derivatives
NZ546834A (en) * 2003-10-01 2010-03-26 Adolor Corp Spirocyclic heterocyclic derivatives and methods of their use
ES2257168B1 (en) * 2004-08-18 2007-06-01 Laboratorios Del Dr Esteve, S.A. 5-HT7 RECEIVER LIGANDS.
EP1838296B1 (en) 2004-10-20 2012-08-08 Resverlogix Corp. Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases
US8163744B2 (en) * 2005-03-18 2012-04-24 Nexuspharma, Inc. Tetrahydro-isoquinolin-1-ones for the treatment of cancer
RU2302417C1 (en) * 2006-03-14 2007-07-10 Иващенко Андрей Александрович 1-oxo-3-(1h-indol-3-yl)-1,2,3,4-tetrahydroisoquinolines, methods of preparation thereof, combinatory library, and focused library
RU2303597C1 (en) * 2006-05-12 2007-07-27 Иващенко Андрей Александрович Pharmaceutical composition, method for its preparing and using
US8367699B2 (en) * 2006-09-15 2013-02-05 Nexuspharma, Inc. Tetrahydro-isoquinolines
WO2008112715A2 (en) * 2007-03-12 2008-09-18 Vm Discovery Inc. Novel agents of calcium ion channel modulators
WO2008131779A1 (en) * 2007-04-26 2008-11-06 H. Lundbeck A/S Isoquinolinone derivatives as nk3 antagonists
EP2149560B1 (en) * 2007-05-22 2015-05-13 Astellas Pharma Inc. 1-substituted tetrahydroisoquinoline compound
JP2011507910A (en) * 2007-12-21 2011-03-10 ユニバーシティー オブ ロチェスター Methods for changing the lifetime of eukaryotes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006115135A1 (en) * 2005-04-21 2006-11-02 Astellas Pharma Inc. Therapeutic agent for irritable bowel syndrome
EP1872795A1 (en) * 2005-04-21 2008-01-02 Astellas Pharma Inc. Therapeutic agent for irritable bowel syndrome

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of WO2008146774A1 *
VALENTINE ET AL.: "CP-70,030 and CP-75,998: The first non-peptide antagonists of bombesin and gastrin releasing peptide", BIOORG. MED. CHEM. LETT., vol. 2, no. 4, 1 January 1992 (1992-01-01), pages 333 - 338, XP026615532, DOI: 10.1016/S0960-894X(01)80213-4 *

Also Published As

Publication number Publication date
RU2009148507A (en) 2011-07-10
DK2149561T3 (en) 2015-12-21
US20140058100A1 (en) 2014-02-27
ES2558677T3 (en) 2016-02-08
KR101580298B1 (en) 2016-01-08
HRP20151336T1 (en) 2016-01-15
WO2008146774A1 (en) 2008-12-04
ZA200908220B (en) 2011-02-23
SI2149561T1 (en) 2016-02-29
HUE026316T2 (en) 2016-06-28
US9526719B2 (en) 2016-12-27
RU2479578C2 (en) 2013-04-20
EP2149561A1 (en) 2010-02-03
US8486970B2 (en) 2013-07-16
CY1117004T1 (en) 2017-04-05
RS54429B1 (en) 2016-04-28
US10532048B2 (en) 2020-01-14
US20100227866A1 (en) 2010-09-09
US9150541B2 (en) 2015-10-06
JPWO2008146774A1 (en) 2010-08-19
MX2009012779A (en) 2010-02-17
US20190000832A1 (en) 2019-01-03
JP5336359B2 (en) 2013-11-06
US10016410B2 (en) 2018-07-10
CA2688326A1 (en) 2008-12-04
AU2008255815B2 (en) 2012-02-02
PL2149561T3 (en) 2016-05-31
BRPI0812359A2 (en) 2015-01-27
CN101668747A (en) 2010-03-10
US20170189390A1 (en) 2017-07-06
CA2688326C (en) 2016-07-05
AU2008255815A1 (en) 2008-12-04
IL202301A0 (en) 2010-06-30
KR20160139067A (en) 2016-12-06
EP2149561B1 (en) 2015-09-09
KR20100020982A (en) 2010-02-23
IL202301A (en) 2017-07-31
TW200911251A (en) 2009-03-16
PT2149561E (en) 2016-01-07
US20150359787A1 (en) 2015-12-17
KR101830566B1 (en) 2018-02-20
KR101682638B1 (en) 2016-12-05
KR20150090262A (en) 2015-08-05
CN101668747B (en) 2012-02-01
TWI425945B (en) 2014-02-11

Similar Documents

Publication Publication Date Title
TWI371277B (en) Salt form
ZA201002608B (en) Azolecarboxamide compound or salt thereof
EP2226315A4 (en) 2-aminoquinazoline derivative
IL202262A0 (en) Bicycloaniline derivative
EP2213673A4 (en) Pyridone-substituted-dihydropyrazolopyrimidinone derivative
IL193422A0 (en) Amide derivative or salt thereof
ZA200908220B (en) Tetrahydroisoquinolin-1-one derivative or salt thereof
ZA200900103B (en) Aminoindane derivative or salt thereof
HK1144196A1 (en) 4-pyrimidinesulfamide derivative 4-
ZA201100032B (en) Triazole derivative or salt thereof
GB0702382D0 (en) New salt
HU0600293D0 (en) New rosuvastatine salt
EP2163554A4 (en) Pyrimidodiazepinone derivative
EP2157084A4 (en) 5-phenyl-3-pyridazinone derivative
EP2228362A4 (en) 4-hydroxyphenylalkylamine derivative
GB0703998D0 (en) Novel salt
GB0717513D0 (en) Salt counter
AP2009005065A0 (en) Sulfonyl-quinoline derivatives

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20091119

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

RAX Requested extension states of the european patent have changed

Extension state: RS

Payment date: 20091119

A4 Supplementary search report drawn up and despatched

Effective date: 20110804

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 417/12 20060101ALI20110729BHEP

Ipc: C07D 405/06 20060101ALI20110729BHEP

Ipc: C07D 401/12 20060101ALI20110729BHEP

Ipc: C07D 401/06 20060101ALI20110729BHEP

Ipc: A61K 31/695 20060101ALI20110729BHEP

Ipc: A61K 31/496 20060101ALI20110729BHEP

Ipc: C07D 217/26 20060101AFI20110729BHEP

Ipc: A61K 31/472 20060101ALI20110729BHEP

Ipc: C07D 401/04 20060101ALI20110729BHEP

Ipc: C07D 413/12 20060101ALI20110729BHEP

Ipc: A61K 31/5377 20060101ALI20110729BHEP

Ipc: A61K 31/497 20060101ALI20110729BHEP

Ipc: C07D 405/14 20060101ALI20110729BHEP

Ipc: A61P 35/00 20060101ALI20110729BHEP

Ipc: A61K 31/506 20060101ALI20110729BHEP

Ipc: C07D 405/04 20060101ALI20110729BHEP

Ipc: A61K 31/53 20060101ALI20110729BHEP

Ipc: A61P 1/00 20060101ALI20110729BHEP

Ipc: C07D 409/12 20060101ALI20110729BHEP

Ipc: A61K 31/501 20060101ALI20110729BHEP

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SELDAR PHARMA INC.

17Q First examination report despatched

Effective date: 20130916

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20150402

RIN1 Information on inventor provided before grant (corrected)

Inventor name: HISAMICHI, HIROYUKI

Inventor name: SHIMADA, ITSURO

Inventor name: ISHIHARA, TSUKASA

Inventor name: ISHIKAWA, NORIKO

Inventor name: MAENO, KYOICHI

Inventor name: SHIMIZU, TAKAFUMI

Inventor name: SEKI, NORIO

Inventor name: TAKUWA, TOMOFUMI

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: RS

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 748018

Country of ref document: AT

Kind code of ref document: T

Effective date: 20150915

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602008040088

Country of ref document: DE

REG Reference to a national code

Ref country code: HR

Ref legal event code: TUEP

Ref document number: P20151336

Country of ref document: HR

REG Reference to a national code

Ref country code: RO

Ref legal event code: EPE

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20151214

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20151207

REG Reference to a national code

Ref country code: HR

Ref legal event code: T1PR

Ref document number: P20151336

Country of ref document: HR

REG Reference to a national code

Ref country code: NO

Ref legal event code: T2

Effective date: 20150909

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2558677

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20160208

REG Reference to a national code

Ref country code: EE

Ref legal event code: FG4A

Ref document number: E011411

Country of ref document: EE

Effective date: 20151215

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: AT

Ref legal event code: UEP

Ref document number: 748018

Country of ref document: AT

Kind code of ref document: T

Effective date: 20150909

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 9

REG Reference to a national code

Ref country code: SK

Ref legal event code: T3

Ref document number: E 20089

Country of ref document: SK

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602008040088

Country of ref document: DE

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20150402625

Country of ref document: GR

Effective date: 20160219

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E026316

Country of ref document: HU

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20160610

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 10

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 11

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20151336

Country of ref document: HR

Payment date: 20190401

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BG

Payment date: 20200317

Year of fee payment: 13

Ref country code: PL

Payment date: 20200313

Year of fee payment: 13

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20151336

Country of ref document: HR

Payment date: 20200406

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CZ

Payment date: 20200515

Year of fee payment: 13

Ref country code: PT

Payment date: 20200616

Year of fee payment: 13

Ref country code: FI

Payment date: 20200511

Year of fee payment: 13

Ref country code: GR

Payment date: 20200409

Year of fee payment: 13

Ref country code: FR

Payment date: 20200414

Year of fee payment: 13

Ref country code: IE

Payment date: 20200513

Year of fee payment: 13

Ref country code: EE

Payment date: 20200429

Year of fee payment: 13

Ref country code: DE

Payment date: 20200512

Year of fee payment: 13

Ref country code: TR

Payment date: 20200522

Year of fee payment: 13

Ref country code: RO

Payment date: 20200429

Year of fee payment: 13

Ref country code: NL

Payment date: 20200513

Year of fee payment: 13

Ref country code: DK

Payment date: 20200512

Year of fee payment: 13

Ref country code: NO

Payment date: 20200511

Year of fee payment: 13

Ref country code: CY

Payment date: 20200408

Year of fee payment: 13

Ref country code: MC

Payment date: 20200430

Year of fee payment: 13

Ref country code: LT

Payment date: 20200423

Year of fee payment: 13

Ref country code: LU

Payment date: 20200511

Year of fee payment: 13

Ref country code: CH

Payment date: 20200515

Year of fee payment: 13

Ref country code: ES

Payment date: 20200601

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20200416

Year of fee payment: 13

Ref country code: SE

Payment date: 20200512

Year of fee payment: 13

Ref country code: HR

Payment date: 20200406

Year of fee payment: 13

Ref country code: GB

Payment date: 20200513

Year of fee payment: 13

Ref country code: IS

Payment date: 20200407

Year of fee payment: 13

Ref country code: SK

Payment date: 20200429

Year of fee payment: 13

Ref country code: IT

Payment date: 20200414

Year of fee payment: 13

Ref country code: LV

Payment date: 20200423

Year of fee payment: 13

Ref country code: SI

Payment date: 20200415

Year of fee payment: 13

Ref country code: HU

Payment date: 20200418

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MT

Payment date: 20200514

Year of fee payment: 13

Ref country code: AT

Payment date: 20200428

Year of fee payment: 13

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602008040088

Country of ref document: DE

REG Reference to a national code

Ref country code: HR

Ref legal event code: PBON

Ref document number: P20151336

Country of ref document: HR

Effective date: 20210526

REG Reference to a national code

Ref country code: FI

Ref legal event code: MAE

REG Reference to a national code

Ref country code: EE

Ref legal event code: MM4A

Ref document number: E011411

Country of ref document: EE

Effective date: 20210531

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

Effective date: 20210531

REG Reference to a national code

Ref country code: NO

Ref legal event code: MMEP

Ref country code: LT

Ref legal event code: MM4D

Effective date: 20210526

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: NL

Ref legal event code: MM

Effective date: 20210601

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 748018

Country of ref document: AT

Kind code of ref document: T

Effective date: 20210526

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20210526

REG Reference to a national code

Ref country code: SK

Ref legal event code: MM4A

Ref document number: E 20089

Country of ref document: SK

Effective date: 20210526

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210527

Ref country code: HR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210526

Ref country code: EE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210531

Ref country code: CZ

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210526

Ref country code: CY

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210526

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210527

Ref country code: SK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210526

Ref country code: FI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210526

Ref country code: RO

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210526

Ref country code: NO

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210531

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20211126

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210531

Ref country code: BG

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20211130

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210526

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210531

Ref country code: LT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210526

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210531

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210526

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20210531

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210527

Ref country code: LV

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210526

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20211207

REG Reference to a national code

Ref country code: SI

Ref legal event code: KO00

Effective date: 20220124

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210526

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210526

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210531

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20211201

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210601

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210531

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210531

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20220803

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210527

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210526

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200526